Profile data is unavailable for this security.
About the company
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
- Revenue in USD (TTM)21.71m
- Net income in USD-62.38m
- Incorporated2022
- Employees106.00
- LocationOmniAb Inc5980 Horton Street, Suite 600EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 250-7800
- Fax+1 (302) 636-5454
- Websitehttps://www.omniab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 516.52m | 31.00 | -- | 2.37 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -299.80m | 528.98m | 130.00 | -- | 0.9287 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 35.19m | -86.45m | 535.03m | 116.00 | -- | -- | -- | 15.21 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 538.01m | 59.00 | -- | 3.53 | -- | 1,315.42 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Neurogene Inc | 925.00k | -55.44m | 540.01m | 91.00 | -- | 3.48 | -- | 583.80 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Eliem Therapeutics Inc | 0.00 | -64.20m | 555.26m | 9.00 | -- | 2.49 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Entrada Therapeutics Inc | 239.40m | 104.44m | 557.99m | 168.00 | 5.07 | 1.30 | 5.17 | 2.33 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 558.91m | 106.00 | -- | 1.90 | -- | 25.74 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Celcuity Inc | 0.00 | -82.59m | 562.49m | 55.00 | -- | 3.18 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 568.43m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 568.86m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 579.49m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Alector Inc | 55.28m | -160.66m | 597.55m | 245.00 | -- | 3.97 | -- | 10.81 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 601.69m | 28.00 | -- | 2.07 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to OmniAb Inc's reporting currency: US Dollar USD
32.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 7.83m | 6.63% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 6.26m | 5.30% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.44m | 3.76% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 3.49m | 2.95% |
| Chicago Capital LLCas of 30 Jun 2024 | 3.18m | 2.69% |
| Rubric Capital Management LPas of 30 Jun 2024 | 2.85m | 2.41% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 2.75m | 2.33% |
| Rice, Hall, James & Associates LLCas of 30 Jun 2024 | 2.56m | 2.17% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.34m | 1.98% |
| Private Management Group, Inc.as of 30 Jun 2024 | 2.26m | 1.91% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
